Abstract
Objective To characterize subphenotypes of self-reported symptoms and outcomes(SRSOs) in Post-acute sequelae of COVID-19(PASC).
Design Prospective, observational cohort study of PASC subjects.
Setting Academic tertiary center from five clinical referral sources.
Participants Adults with COVID-19 ≥ 20 days before enrollment and presence of any new self-reported symptoms following COVID-19.
Exposures We collected data on clinical variables and SRSOs via structured telephone interviews and performed standardized assessments with validated clinical numerical scales to capture psychological symptoms, neurocognitive functioning, and cardiopulmonary function. We collected saliva and stool samples for quantification of SARS-CoV-2 RNA via qPCR.
Primary and Secondary outcomes of measure Description of PASC SRSOs burden and duration, derivation of distinct PASC subphenotypes via latent class analysis (LCA), and relationship between viral load with SRSOs and PASC subphenotypes.
Results Baseline data for 214 individuals were analyzed. The study visit took place at a median of 197.5 days after COVID-19 diagnosis, and participants reported ever having a median of 9/16 symptoms (interquartile range 6-11) after acute COVID, with muscle-aches, dyspnea, and headache being the most common. Fatigue, cognitive impairment, and dyspnea were experienced for a longer time. Participants had a lower burden of active symptoms (median 3, interquartile range 1-6) than those ever experienced (p<0.001). Unsupervised LCA of symptoms revealed three clinically-active PASC subphenotypes: a high burden constitutional symptoms (21.9%), a persistent loss/change of smell and taste (20.6%), and a minimal residual symptoms subphenotype (57.5%). Subphenotype assignments were strongly associated with self-assessments of global health, recovery and PASC impact on employment (p<0.001). Viral persistence (5.6% saliva and 1% stool samples positive) did not explain SRSOs or subphenotypes.
Conclusions We identified distinct PASC subphenotypes and highlight that although most symptoms progressively resolve, specific PASC subpopulations are impacted by either high burden of constitutional symptoms or persistent olfactory/gustatory dysfunction, requiring prospective identification and targeted preventive or therapeutic interventions.
Strengths and Limitations of this study
Prospective cohort study with inclusive patient population with PASC symptomatology from different clinical sources and index severity of COVID-19.
Structured telephone interviews and standardized assessments with validated clinical numerical scales
Unsupervised clustering analysis for data-driven derivation of PASC subphenotypes.
Analyses based on self-reported symptoms and outcomes, but not on physiologic or imaging measurements.
Non-invasive biospecimen for analysis of viral persistence may have missed viral signal in deep-seeded tissues.
Question Are there distinct subphenotypes of self-reported symptoms and outcomes in subjects with PASC and what if so, which factors predict them?
Findings This prospective observational cohort study identified three distinct PASC clusters, comprising a high burden cluster with constitutional symptoms (21.9%), a cluster characterized by persistent loss/change of smell and taste (20.6%), and a minimal residual symptoms cluster (57.5%).
Meaning PASC subphenotypes offer insights into the symptoms and outcomes experienced by individuals, and provide a framework for targeted study of preventive and therapeutic interventions.
Competing Interest Statement
Dr. Kitsios has received research funding from Karius, Inc. Drs. Kitsios, Morris, Mellors, Sciurba and Nouraie have received funding from Pfizer, Inc. Dr. Mellors is a consultant to Gilead Sciences and owns shares or share options in Co-Crystal Pharmaceuticals, ID Connect, and Abound Bio, all unrelated to the current work. All other authors disclosed no conflict of interest.
Funding Statement
Funding information: This work was supported by a research grant from Pfizer, Inc to the University of Pittsburgh.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval and consent to participate: The University of Pittsburgh Institutional Review Board (IRB) approved the study protocol STUDY21010001. We obtained written or electronic informed consent by all participants in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Availability of data and material: All data generated or analyzed during this study are included in this article and its supplementary information files.
